Roivant Sciences Ltd. vs Eli Lilly & Co.
ROIV vs LLY — side-by-side comparison from reported financials. ROIV leads 3, LLY leads 7 of 10 comparable metrics.
Roivant Sciences Ltd.
ROIV · Healthcare
$35.44+3.60%Strong
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | ROIV | LLY |
|---|---|---|
| Price | $35.44 | $1 177.20 |
| Market cap | $25.6B | $1.05T |
| Revenue (TTM) | $16.9M | $79.7B |
| Revenue growth | -48.7% | +31.7% |
| Net margin | -7594.2% | 33.5% |
| Free cash flow | -$1.89B | $18.2B |
| Net cash (debt) | $3.73B | ($35.2B) |
| 1-year price return | +119.9% | +37.6% |
| P/E | — | 41.6 |
| P/E vs own history (cheap-side %) | 73% | 88% |
| Dividend yield | — | 0.52% |
| Return on equity | -6% | 93% |
| Altman Z-score | 40.50 | 7.10 |
| CV checks passed | 5 of 9 | 11 of 9 |
| Employees | 721 | 50,000 |
Full résumé-style profiles: ROIV CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.